Antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1/ligand (PD-1/PD-L1) have increasingly become new standards of care in several types of cancers [3,4,5]. The gene discussed is PDCD1; the disease is cancer.